

**Note to readers with disabilities:** *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact [ehp508@niehs.nih.gov](mailto:ehp508@niehs.nih.gov). Our staff will work with you to assess and meet your accessibility needs within 3 working days.

### **Supplemental Material**

#### **Ambient Air Pollution and Cancer Mortality in the Cancer Prevention Study-II**

Michelle C. Turner, Daniel Krewski, W. Ryan Diver, C. Arden Pope III, Richard T. Burnett, Michael Jerrett, Julian D. Marshall, Susan M. Gapstur

#### **Table of Contents**

**Table S1.** Correlations between air pollutants (n = 623,048).

**Table S2.** Distribution of additional participant characteristics at enrollment (1982) and air pollution concentrations, CPS-II cohort, US (n = 623,048).

**Table S3.** Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, single-pollutant models with minimal adjustment, CPS-II cohort, US (1982-2004) (n = 623,048).

**Table S4.** Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, single-pollutant models, sensitivity analysis adjusting for physical exercise, aspirin use, and red meat intake, CPS-II cohort, US (1982-2004) (n = 623,048).

**Table S5.** Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, single-pollutant models, sensitivity analysis adjusting for age at menarche, parity, age at first birth, oral contraceptive use, menopausal status, and postmenopausal hormone use, females, CPS-II cohort, US (1982-2004) (n = 344,593).

**Table S6.** Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, two-pollutant model, CPS-II cohort, US (1982-2004) (n = 623,048).

**Table S7.** Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, multi-pollutant models, CPS-II cohort, US (1982-2004) (n = 623,048).

**Table S8.** Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in decomposed LURBME PM<sub>2.5</sub> concentrations, two-pollutant model, CPS-II cohort, US (1982-2004) (n = 623,048).

**Table S9.** Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, stratified results according to selected risk factors, CPS-II cohort, US (1982-2004).

Table S1. Correlations between air pollutants (n = 623,048).

	PM <sub>2.5</sub>	NO <sub>2</sub>	O <sub>3</sub>	Near-source PM <sub>2.5</sub>	Regional PM <sub>2.5</sub>
PM <sub>2.5</sub>	-	0.40	0.17	0.27	0.94
NO <sub>2</sub>	-	-	-0.09	0.60	0.21
O <sub>3</sub>	-	-	-	-0.13	0.22
Near-source PM <sub>2.5</sub>	-	-	-	-	-0.06
Regional PM <sub>2.5</sub>	-	-	-	-	-

Table 2. Distribution of additional participant characteristics at enrollment (1982) and air pollution concentrations, CPS-II cohort, US (n = 623,048).

Characteristic	%	PM <sub>2.5</sub> (µg/m <sup>3</sup> ) Mean (SD)	NO <sub>2</sub> (ppb) Mean (SD)	O <sub>3</sub> (ppb) Mean (SD)
<b>Exercise</b>				
None	2.2	12.9 (2.8)	13.2 (5.6)	37.8 (4.0)
Slight	24.5	12.7 (2.9)	12.1 (5.2)	38.1 (4.0)
Moderate	64.6	12.5 (2.8)	11.4 (5.0)	38.2 (3.9)
Heavy	7.5	12.5 (2.9)	11.3 (5.1)	38.2 (4.0)
Missing	1.2	12.7 (2.8)	11.8 (5.2)	38.0 (3.9)
<b>Aspirin Use Past Month</b>				
Yes	26.0	12.5 (2.8)	11.5 (5.0)	38.1 (3.9)
No	74.0	12.6 (2.9)	11.7 (5.1)	38.2 (4.0)
<b>Red Meat Consumption</b>				
1 <sup>st</sup> quintile	16.6	12.7 (3.0)	12.7 (5.5)	37.9 (4.3)
2 <sup>nd</sup> quintile	19.5	12.6 (2.8)	12.0 (5.2)	38.0 (4.0)
3 <sup>rd</sup> quintile	21.2	12.5 (2.8)	11.5 (5.0)	38.0 (3.9)
4 <sup>th</sup> quintile	15.4	12.5 (2.8)	11.1 (4.8)	38.2 (3.8)
5 <sup>th</sup> quintile	19.1	12.5 (2.8)	10.7 (4.6)	38.4 (3.7)
<b>Age at Menarche<sup>a</sup></b>				
<12 years	17.7	12.6 (2.9)	11.9 (5.2)	38.1 (3.9)
12-13 years	53.0	12.6 (2.8)	11.6 (5.1)	38.1 (3.9)
14+ years	26.4	12.6 (2.9)	11.6 (5.1)	38.2 (4.0)
Missing	2.9	12.7 (2.8)	11.6 (5.0)	38.3 (3.9)
<b>Parity<sup>a</sup></b>				
0	11.8	12.8 (2.9)	12.2 (5.2)	38.0 (4.0)
1	10.8	12.8 (2.9)	11.8 (5.1)	38.3 (3.9)
2	27.0	12.7 (2.9)	11.8 (5.2)	38.1 (3.9)
3	22.8	12.5 (2.8)	11.5 (5.1)	38.1 (3.9)
4+	24.3	12.4 (2.8)	11.4 (5.0)	38.2 (4.0)
Missing	3.4	12.8 (2.8)	12.1 (5.3)	38.0 (3.9)
<b>Age at First Birth<sup>a</sup></b>				
No birth	11.8	12.8 (2.9)	12.2 (5.2)	38.0 (4.0)
<20 years	9.8	12.6 (3.0)	11.1 (4.9)	38.7 (4.0)
20-29 years	64.6	12.6 (2.8)	11.6 (5.1)	38.1 (3.9)
30+ years	9.6	12.7 (2.9)	12.1 (5.2)	37.9 (4.0)
Missing	4.3	12.8 (2.8)	12.1 (5.2)	38.0 (3.9)
<b>Ever Oral Contraceptive Use<sup>a</sup></b>				
Yes	28.3	12.5 (2.9)	11.4 (5.0)	38.1 (4.0)
No	68.6	12.6 (2.8)	11.8 (5.2)	38.2 (3.9)
Missing	3.0	12.8 (2.8)	11.9 (5.2)	38.2 (3.7)
<b>Post-Menopausal Status<sup>a</sup></b>				
Yes	69.9	12.6 (2.9)	11.6 (5.0)	38.2 (4.0)
No	27.8	12.6 (2.8)	11.8 (5.3)	37.9 (3.9)
Missing	2.3	12.7 (2.9)	11.4 (4.9)	38.5 (3.8)
<b>Ever Postmenopausal Hormone Use<sup>a</sup></b>				
Yes	33.6	12.5 (3.0)	11.5 (4.9)	38.5 (4.2)
No	57.7	12.6 (2.8)	11.7 (5.2)	38.0 (3.8)
Missing	8.7	12.8 (2.8)	11.9 (5.2)	38.0 (3.8)
<b>Diabetes</b>				
Yes	4.7	12.8 (2.8)	11.8 (5.1)	38.3 (3.9)
No	95.3	12.6 (2.8)	11.6 (5.1)	38.1 (4.0)

<sup>a</sup>Limited to 344,593 women.

Table S3. Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, single-pollutant models with minimal adjustment, CPS-II cohort, US (1982-2004) (n = 623,048).

Cause of Death	ICD 9; 10	No. of Deaths	PM <sub>2.5</sub>		NO <sub>2</sub>		O <sub>3</sub>	
			HR	95% CI	HR	95% CI	HR	95% CI
			per 4.4 µg/m <sup>3</sup>		per 6.5 ppb		per 6.9 ppb	
Tongue and mouth	141, 143-145; C01-C06	262	1.12	0.94-1.35	1.10	0.95-1.28	0.87	0.70-1.07
Salivary gland	142; C07-C08	58	1.11	0.75-1.64	1.23	0.91-1.67	1.22	0.80-1.87
Pharynx	146-149; C09-C14	243	0.95	0.78-1.16	0.89	0.75-1.06	1.06	0.86-1.32
Esophagus	150; C15	1,180	1.00	0.91-1.09	1.03	0.96-1.11	<b>0.89</b>	<b>0.80-0.98</b>
Stomach	151; C16	1,340	1.03	0.95-1.11	<b>1.08</b>	<b>1.01-1.15</b>	<b>0.89</b>	<b>0.81-0.98</b>
Colorectal	153-154; C18-C21	6,475	<b>1.07</b>	<b>1.03-1.11</b>	<b>1.04</b>	<b>1.01-1.07</b>	<b>0.92</b>	<b>0.88-0.96</b>
Liver	155; C22	1,003	1.07	0.97-1.17	1.05	0.97-1.13	0.97	0.87-1.08
Gallbladder	156; C23-C24	403	1.03	0.89-1.20	1.00	0.88-1.13	0.89	0.76-1.06
Pancreas	157; C25	3,812	1.00	0.96-1.06	<b>1.05</b>	<b>1.01-1.10</b>	<b>0.90</b>	<b>0.85-0.95</b>
Nose	160; C30-C31	46	<b>0.55</b>	<b>0.34-0.90</b>	0.75	0.49-1.14	1.10	0.68-1.79
Larynx	161; C32	223	1.14	0.93-1.39	1.15	0.98-1.35	0.94	0.75-1.18
Bone	170; C40-C41	81	0.92	0.65-1.29	0.98	0.74-1.30	1.03	0.71-1.50
Connective tissue	171; C47, C49	377	1.03	0.88-1.20	1.04	0.91-1.18	0.88	0.74-1.05
Melanoma	172; C43	862	1.02	0.92-1.13	1.03	0.95-1.13	0.97	0.86-1.09
Other skin	173; C44, C46	195	1.07	0.87-1.33	1.04	0.87-1.25	0.98	0.77-1.25
Breast (female) <sup>b</sup>	174-175; C50	3,844	<b>1.08</b>	<b>1.02-1.13</b>	<b>1.05</b>	<b>1.01-1.09</b>	0.98	0.92-1.03
Uterus <sup>b,c</sup>	179, 182; C54-C55	611	1.05	0.93-1.19	1.05	0.95-1.15	0.99	0.86-1.14
Cervix <sup>b,c</sup>	180; C53	115	<b>1.35</b>	<b>1.03-1.78</b>	1.04	0.83-1.30	1.02	0.74-1.41
Ovary <sup>b,c,d</sup>	183; C56	987	0.99	0.90-1.10	0.99	0.91-1.07	1.00	0.90-1.11
Prostate <sup>b</sup>	185; C61	1,068	0.96	0.87-1.05	0.98	0.91-1.06	0.99	0.90-1.10
Bladder	188; C67	1,324	<b>1.13</b>	<b>1.04-1.22</b>	<b>1.08</b>	<b>1.01-1.15</b>	0.95	0.86-1.04
Kidney	189; C64-C66, C68	927	1.09	0.99-1.20	0.99	0.91-1.08	0.96	0.86-1.07
Eye	190; C69	26	0.86	0.47-1.58	0.95	0.57-1.59	0.71	0.36-1.40
Brain	191; C71	1,591	1.01	0.94-1.09	0.97	0.91-1.03	0.97	0.89-1.05
Thyroid	193; C73	41	0.66	0.40-1.09	1.12	0.77-1.64	0.99	0.58-1.68
Non-Hodgkin's lymphoma	200,202; C82-C85	2,840	1.02	0.96-1.08	1.04	0.99-1.09	0.98	0.92-1.05
Hodgkin's disease	201; C81	125	1.10	0.84-1.43	1.09	0.88-1.36	0.98	0.72-1.32
Multiple myeloma	203; C88, C90	1,421	0.97	0.89-1.05	0.98	0.92-1.05	1.01	0.92-1.11
Leukemia	204-208; C91-C95	2,584	1.02	0.97-1.09	1.02	0.97-1.07	0.94	0.88-1.01

<sup>a</sup> Age, race/ethnicity, gender, stratified.

<sup>b</sup> As above but not gender stratified. Analysis limited to 344,593 women for analysis of breast cancer mortality, 235,637 women for analysis of uterine or cervical cancer mortality, and 228,494 women for analysis of ovarian cancer mortality. Analysis limited to 278,455 men for analysis of prostate cancer mortality.

<sup>c</sup> Women reporting a previous hysterectomy or an artificial menopause excluded here (n = 108,956).

<sup>d</sup> Women reporting having undergone an ovarian surgery also excluded here (n = 7,143).

Table S4. Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, single-pollutant models, sensitivity analysis adjusting for physical exercise, aspirin use, and red meat intake, CPS-II cohort, US (1982-2004) (n = 623,048).

Cause of Death	ICD 9; 10	No. of Deaths	PM <sub>2.5</sub>		NO <sub>2</sub>		O <sub>3</sub>	
			HR	95% CI	HR	95% CI	HR	95% CI
			per 4.4 µg/m <sup>3</sup>		per 6.5 ppb		per 6.9 ppb	
Tongue and mouth	141, 143-145; C01-C06	262	1.03	0.84-1.26	0.97	0.79-1.17	0.93	0.73-1.17
Salivary gland	142; C07-C08	58	0.93	0.60-1.43	1.00	0.67-1.49	1.44	0.90-2.29
Pharynx	146-149; C09-C14	243	0.88	0.70-1.10	0.86	0.68-1.07	1.11	0.86-1.42
Esophagus	150; C15	1,180	1.02	0.92-1.12	1.01	0.92-1.11	0.97	0.86-1.08
Stomach	151; C16	1,340	1.00	0.91-1.09	1.05	0.96-1.14	<b>0.90</b>	<b>0.81-0.99</b>
Colorectal	153-154; C18-C21	6,475	1.04	1.00-1.08	<b>1.06</b>	<b>1.01-1.10</b>	<b>0.95</b>	<b>0.90-0.99</b>
Liver	155; C22	1,003	1.04	0.93-1.15	1.05	0.94-1.16	0.97	0.86-1.09
Gallbladder	156; C23-C24	403	1.03	0.87-1.22	1.00	0.85-1.17	0.95	0.78-1.14
Pancreas	157; C25	3,812	0.98	0.92-1.03	1.04	0.98-1.09	<b>0.91</b>	<b>0.85-0.97</b>
Nose	160; C30-C31	46	0.65	0.37-1.16	0.83	0.47-1.42	1.19	0.69-2.05
Larynx	161; C32	223	1.04	0.83-1.30	1.06	0.85-1.31	0.96	0.73-1.24
Bone	170; C40-C41	81	0.81	0.54-1.18	0.96	0.67-1.37	0.94	0.61-1.41
Connective tissue	171; C47, C49	377	1.06	0.89-1.25	1.04	0.88-1.23	0.89	0.73-1.07
Melanoma	172; C43	862	1.05	0.93-1.17	0.97	0.86-1.08	1.02	0.89-1.15
Other skin	173; C44, C46	195	1.10	0.88-1.38	0.89	0.70-1.13	0.97	0.75-1.25
Breast (female) <sup>b</sup>	174-175; C50	3,844	1.02	0.97-1.08	1.03	0.97-1.08	0.99	0.92-1.05
Uterus <sup>b,c</sup>	179, 182; C54-C55	611	1.04	0.90-1.19	1.07	0.93-1.21	0.98	0.84-1.14
Cervix <sup>b,c</sup>	180; C53	115	1.35	0.98-1.83	1.25	0.92-1.69	1.00	0.68-1.47
Ovary <sup>b,c,d</sup>	183; C56	987	1.03	0.92-1.15	1.03	0.92-1.13	1.01	0.89-1.14
Prostate <sup>b</sup>	185; C61	1,068	0.96	0.86-1.06	1.01	0.91-1.11	1.03	0.92-1.15
Bladder	188; C67	1,324	<b>1.13</b>	<b>1.03-1.23</b>	1.02	0.93-1.11	1.03	0.92-1.13
Kidney	189; C64-C66, C68	927	<b>1.14</b>	<b>1.02-1.27</b>	0.99	0.88-1.09	0.97	0.85-1.09
Eye	190; C69	26	1.28	0.65-2.49	1.15	0.57-2.30	0.76	0.38-1.53
Brain	191; C71	1,591	1.04	0.95-1.13	0.99	0.91-1.07	0.98	0.89-1.07
Thyroid	193; C73	41	0.61	0.34-1.11	1.19	0.72-1.97	0.96	0.54-1.71
Non-Hodgkin's lymphoma	200,202; C82-C85	2,840	1.00	0.94-1.06	1.05	0.98-1.11	0.98	0.91-1.05
Hodgkin's disease	201; C81	125	1.13	0.82-1.54	1.15	0.86-1.51	1.08	0.76-1.53
Multiple myeloma	203; C88, C90	1,421	0.97	0.89-1.06	1.00	0.91-1.09	0.99	0.89-1.09

Leukemia	204-208; C91-C95	2,584	1.01	0.94-1.07	1.00	0.94-1.07	<b>0.92</b>	<b>0.85-0.98</b>
----------	------------------	-------	------	-----------	------	-----------	-------------	------------------

<sup>a</sup> Age, race/ethnicity, gender stratified, and adjusted for baseline values of education, marital status, body mass index, body mass index squared, smoking status, cigarettes per day, cigarettes per day squared, duration of smoking, duration of smoking squared, age started smoking, passive smoking, vegetable/fruit/fiber consumption, fat consumption, beer, wine, liquor consumption, industrial exposures, occupation dirtiness index, and 1990 ecological covariates.

<sup>b</sup> As above but not gender stratified. Analysis limited to 344,593 women for analysis of breast cancer mortality, 235,637 women for analysis of uterine or cervical cancer mortality, and 228,494 women for analysis of ovarian cancer mortality. Analysis limited to 278,455 men for analysis of prostate cancer mortality.

<sup>c</sup> Women reporting a previous hysterectomy or an artificial menopause excluded here (n = 108,956).

<sup>d</sup> Women reporting having undergone an ovarian surgery also excluded here (n = 7,143).

Table S5. Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, single-pollutant models, sensitivity analysis adjusting for age at menarche, parity, age at first birth, oral contraceptive use, menopausal status, and postmenopausal hormone use, females, CPS-II cohort, US (1982-2004) (n = 344,593).

Cause of Death	ICD 9; 10	No. of Deaths	PM <sub>2.5</sub>		NO <sub>2</sub>		O <sub>3</sub>	
			HR	95% CI	HR	95% CI	HR	95% CI
Breast (female)	174-175; C50	3,844	1.02	0.97-1.08	1.02	0.97-1.07	1.00	0.94-1.06
Uterus <sup>b</sup>	179, 182; C54-C55	611	1.03	0.90-1.18	1.06	0.94-1.21	0.98	0.84-1.14
Cervix <sup>b</sup>	180; C53	115	1.34	0.98-1.83	1.24	0.92-1.68	1.01	0.69-1.48
Ovary <sup>b,c</sup>	183; C56	987	1.03	0.92-1.15	1.02	0.92-1.13	1.01	0.90-1.14

<sup>a</sup> Age and race/ethnicity stratified, and adjusted for baseline values of education, marital status, body mass index, body mass index squared, smoking status, cigarettes per day, cigarettes per day squared, duration of smoking, duration of smoking squared, age started smoking, passive smoking, vegetable/fruit/fiber consumption, fat consumption, beer, wine, liquor consumption, industrial exposures, occupation dirtiness index, age at menarche, parity, age at first birth, oral contraceptive use, menopausal status, and postmenopausal hormone use, and 1990 ecological covariates.

<sup>b</sup> Women reporting a previous hysterectomy or an artificial menopause excluded here (n = 108,956).

<sup>c</sup> Women reporting having undergone an ovarian surgery also excluded here (n = 7,143).

Table S6. Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, two-pollutant model, CPS-II cohort, US (1982-2004) (n = 623,048).

Cause of Death	ICD 9; 10	No. of Deaths	PM <sub>2.5</sub>		NO <sub>2</sub>	
			HR	95% CI	HR	95% CI
			per 4.4 µg/m <sup>3</sup>		per 6.5 ppb	
Tongue and mouth	141, 143-145; C01-C06	262	1.05	0.84-1.31	0.96	0.77-1.19
Salivary gland	142; C07-C08	58	0.93	0.58-1.48	1.02	0.67-1.58
Pharynx	146-149; C09-C14	243	0.92	0.72-1.18	0.89	0.70-1.14
Esophagus	150; C15	1,180	1.02	0.92-1.14	1.01	0.91-1.12
Stomach	151; C16	1,340	0.97	0.88-1.07	1.06	0.97-1.17
Colorectal	153-154; C18-C21	6,475	1.02	0.97-1.06	<b>1.05</b>	<b>1.01-1.10</b>
Liver	155; C22	1,003	1.04	0.93-1.17	1.01	0.91-1.13
Gallbladder	156; C23-C24	403	1.04	0.87-1.25	0.99	0.83-1.18
Pancreas	157; C25	3,812	0.95	0.90-1.01	1.06	1.00-1.12
Nose	160; C30-C31	46	0.66	0.36-1.24	0.96	0.53-1.75
Larynx	161; C32	223	1.02	0.80-1.29	1.06	0.84-1.34
Bone	170; C40-C41	81	0.80	0.52-1.21	1.05	0.72-1.54
Connective tissue	171; C47, C49	377	1.05	0.87-1.27	1.02	0.85-1.22
Melanoma	172; C43	862	1.08	0.95-1.22	0.94	0.83-1.06
Other skin	173; C44, C46	195	1.19	0.93-1.54	0.84	0.64-1.08
Breast (female) <sup>b</sup>	174-175; C50	3,844	1.02	0.96-1.08	1.02	0.96-1.08
Uterus <sup>b,c</sup>	179, 182; C54-C55	611	1.01	0.87-1.17	1.06	0.92-1.23
Cervix <sup>b,c</sup>	180; C53	115	1.28	0.91-1.80	1.11	0.80-1.56
Ovary <sup>b,c,d</sup>	183; C56	987	1.02	0.91-1.15	1.02	0.91-1.14
Prostate <sup>b</sup>	185; C61	1,068	0.94	0.84-1.06	1.04	0.93-1.16
Bladder	188; C67	1,324	<b>1.14</b>	<b>1.04-1.26</b>	0.97	0.88-1.07
Kidney	189; C64-C66, C68	927	<b>1.19</b>	<b>1.05-1.34</b>	0.92	0.82-1.04
Eye	190; C69	26	1.28	0.61-2.67	1.03	0.48-2.20
Brain	191; C71	1,591	1.05	0.96-1.16	0.97	0.89-1.07
Thyroid	193; C73	41	<b>0.52</b>	<b>0.28-0.97</b>	1.56	0.92-2.65
Non-Hodgkin's lymphoma	200,202; C82-C85	2,840	0.98	0.91-1.05	1.06	0.99-1.13
Hodgkin's disease	201; C81	125	1.07	0.76-1.49	1.13	0.84-1.54
Multiple myeloma	203; C88, C90	1,421	0.97	0.88-1.07	1.02	0.93-1.12

Leukemia	204-208; C91-C95	2,584	1.01	0.94-1.08	1.00	0.93-1.08
----------	------------------	-------	------	-----------	------	-----------

<sup>a</sup> Age, race/ethnicity, gender stratified, and adjusted for baseline values of education, marital status, body mass index, body mass index squared, smoking status, cigarettes per day, cigarettes per day squared, duration of smoking, duration of smoking squared, age started smoking, passive smoking, vegetable/fruit/fiber consumption, fat consumption, beer, wine, liquor consumption, industrial exposures, occupation dirtiness index, and 1990 ecological covariates.

<sup>b</sup> As above but not gender stratified. Analysis limited to 344,593 women for analysis of breast cancer mortality, 235,637 women for analysis of uterine or cervical cancer mortality, and 228,494 women for analysis of ovarian cancer mortality. Analysis limited to 278,455 men for analysis of prostate cancer mortality.

<sup>c</sup> Women reporting a previous hysterectomy or an artificial menopause excluded here (n = 108,956).

<sup>d</sup> Women reporting having undergone an ovarian surgery also excluded here (n = 7,143).

Table S7. Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, multi-pollutant models, CPS-II cohort, US (1982-2004) (n = 623,048).

Cause of Death	ICD 9; 10	No. of Deaths	PM <sub>2.5</sub>		NO <sub>2</sub>		O <sub>3</sub>	
			HR	95% CI	HR	95% CI	HR	95% CI
			per 4.4 µg/m <sup>3</sup>		per 6.5 ppb		per 6.9 ppb	
Tongue and mouth	141, 143-145; C01-C06	262	1.08	0.85-1.37	0.94	0.76-1.17	0.91	0.71-1.16
Salivary gland	142; C07-C08	58	0.82	0.51-1.32	1.10	0.71-1.69	1.52	0.94-2.46
Pharynx	146-149; C09-C14	243	0.89	0.69-1.15	0.91	0.71-1.16	1.14	0.88-1.47
Esophagus	150; C15	1,180	1.03	0.92-1.15	1.00	0.90-1.11	0.96	0.86-1.08
Stomach	151; C16	1,340	1.00	0.90-1.11	1.05	0.95-1.15	0.90	0.81-1.00
Colorectal	153-154; C18-C21	6,475	1.03	0.98-1.08	1.04	1.00-1.09	<b>0.94</b>	<b>0.90-0.99</b>
Liver	155; C22	1,003	1.05	0.93-1.19	1.01	0.90-1.13	0.97	0.86-1.09
Gallbladder	156; C23-C24	403	1.06	0.87-1.28	0.98	0.82-1.17	0.93	0.77-1.13
Pancreas	157; C25	3,812	0.97	0.92-1.04	1.05	0.99-1.11	<b>0.92</b>	<b>0.86-0.98</b>
Nose	160; C30-C31	46	0.62	0.33-1.17	0.96	0.53-1.76	1.32	0.76-2.29
Larynx	161; C32	223	1.03	0.80-1.33	1.06	0.83-1.34	0.95	0.73-1.25
Bone	170; C40-C41	81	0.80	0.52-1.22	1.05	0.72-1.54	1.00	0.65-1.52
Connective tissue	171; C47, C49	377	1.09	0.90-1.33	1.00	0.83-1.20	0.87	0.71-1.06
Melanoma	172; C43	862	1.08	0.95-1.23	0.94	0.83-1.06	1.00	0.88-1.14
Other skin	173; C44, C46	195	1.23	0.94-1.61	0.83	0.64-1.07	0.91	0.70-1.19
Breast (female) <sup>b</sup>	174-175; C50	3,844	1.02	0.96-1.09	1.02	0.96-1.08	0.98	0.92-1.05
Uterus <sup>b,c</sup>	179, 182; C54-C55	611	1.02	0.87-1.19	1.06	0.92-1.22	0.98	0.83-1.15
Cervix <sup>b,c</sup>	180; C53	115	1.30	0.91-1.86	1.10	0.78-1.56	0.95	0.63-1.42
Ovary <sup>b,c,d</sup>	183; C56	987	1.02	0.90-1.16	1.02	0.91-1.14	1.01	0.89-1.14
Prostate <sup>b</sup>	185; C61	1,068	0.93	0.83-1.05	1.04	0.93-1.16	1.05	0.94-1.18
Bladder	188; C67	1,324	<b>1.15</b>	<b>1.03-1.27</b>	0.97	0.88-1.07	0.99	0.89-1.10
Kidney	189; C64-C66, C68	927	<b>1.22</b>	<b>1.07-1.38</b>	0.91	0.81-1.03	0.92	0.81-1.04
Eye	190; C69	26	1.46	0.66-3.25	0.97	0.45-2.10	0.68	0.32-1.44
Brain	191; C71	1,591	1.06	0.97-1.17	0.97	0.89-1.06	0.96	0.87-1.06
Thyroid	193; C73	41	<b>0.51</b>	<b>0.27-0.96</b>	1.57	0.92-2.67	1.09	0.61-1.92
Non-Hodgkin's lymphoma	200,202; C82-C85	2,840	0.98	0.91-1.05	1.06	0.99-1.13	0.99	0.92-1.06
Hodgkin's disease	201; C81	125	1.05	0.74-1.48	1.15	0.84-1.56	1.09	0.76-1.55
Multiple myeloma	203; C88, C90	1,421	0.97	0.88-1.07	1.02	0.92-1.12	1.00	0.90-1.10
Leukemia	204-208; C91-C95	2,584	1.03	0.96-1.11	0.99	0.92-1.06	<b>0.91</b>	<b>0.85-0.98</b>

<sup>a</sup> Age, race/ethnicity, gender stratified, and adjusted for baseline values of education, marital status, body mass index, body mass index squared, smoking status, cigarettes per day, cigarettes per day squared, duration of smoking, duration of smoking squared, age started smoking, passive smoking, vegetable/fruit/fiber consumption, fat consumption, beer, wine, liquor consumption, industrial exposures, occupation dirtiness index, and 1990 ecological covariates.

<sup>b</sup> As above but not gender stratified. Analysis limited to 344,593 women for analysis of breast cancer mortality, 235,637 women for analysis of uterine or cervical cancer mortality, and 228,494 women for analysis of ovarian cancer mortality. Analysis limited to 278,455 men for analysis of prostate cancer mortality.

<sup>c</sup> Women reporting a previous hysterectomy or an artificial menopause excluded here (n = 108,956).

<sup>d</sup> Women reporting having undergone an ovarian surgery also excluded here (n = 7,143).

Table S8. Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in decomposed LURBME PM<sub>2.5</sub> concentrations, two-pollutant model, CPS-II cohort, US (1982-2004) (n = 623,048).

Cause of Death	ICD 9; 10	No. of Deaths	Near-source PM <sub>2.5</sub>		Regional PM <sub>2.5</sub>	
			HR	95% CI	HR	95% CI
			per 1.6 µg/m <sup>3</sup>		per 4.5 µg/m <sup>3</sup>	
Tongue and mouth	141, 143-145; C01-C06	262	1.07	0.85-1.35	1.01	0.82-1.26
Salivary gland	142; C07-C08	58	0.79	0.51-1.25	0.99	0.63-1.56
Pharynx	146-149; C09-C14	243	0.94	0.74-1.19	0.88	0.69-1.12
Esophagus	150; C15	1,180	0.98	0.88-1.10	1.03	0.93-1.15
Stomach	151; C16	1,340	<b>1.13</b>	<b>1.02-1.26</b>	0.97	0.88-1.06
Colorectal	153-154; C18-C21	6,475	<b>1.09</b>	<b>1.04-1.15</b>	1.02	0.97-1.07
Liver	155; C22	1,003	1.08	0.96-1.22	1.03	0.92-1.15
Gallbladder	156; C23-C24	403	1.18	0.97-1.43	0.99	0.83-1.19
Pancreas	157; C25	3,812	1.06	1.00-1.13	0.96	0.90-1.01
Nose	160; C30-C31	46	0.74	0.44-1.27	0.68	0.37-1.24
Larynx	161; C32	223	1.12	0.87-1.44	1.02	0.80-1.28
Bone	170; C40-C41	81	0.81	0.53-1.22	0.85	0.56-1.28
Connective tissue	171; C47, C49	377	1.14	0.94-1.39	1.03	0.86-1.24
Melanoma	172; C43	862	0.95	0.84-1.08	1.07	0.95-1.21
Other skin	173; C44, C46	195	1.26	0.96-1.65	1.05	0.83-1.34
Breast (female) <sup>b</sup>	174-175; C50	3,844	1.01	0.95-1.07	1.03	0.97-1.09
Uterus <sup>b,c</sup>	179, 182; C54-C55	611	1.05	0.89-1.22	1.03	0.89-1.19
Cervix <sup>b,c</sup>	180; C53	115	1.27	0.87-1.85	1.30	0.94-1.82
Ovary <sup>b,c,d</sup>	183; C56	987	0.99	0.87-1.11	1.04	0.93-1.17
Prostate <sup>b</sup>	185; C61	1,068	1.00	0.89-1.12	0.95	0.85-1.07
Bladder	188; C67	1,324	1.02	0.92-1.13	<b>1.14</b>	<b>1.04-1.25</b>
Kidney	189; C64-C66, C68	927	1.05	0.92-1.18	<b>1.15</b>	<b>1.02-1.29</b>
Eye	190; C69	26	1.64	0.75-3.59	1.19	0.59-2.42
Brain	191; C71	1,591	1.03	0.94-1.13	1.04	0.95-1.14
Thyroid	193; C73	41	0.95	0.51-1.76	0.60	0.32-1.12
Non-Hodgkin's lymphoma	200,202; C82-C85	2,840	1.06	0.99-1.14	0.99	0.92-1.06
Hodgkin's disease	201; C81	125	1.32	0.92-1.88	1.05	0.75-1.47

Multiple myeloma	203; C88, C90	1,421	1.01	0.92-1.12	0.97	0.88-1.06
Leukemia	204-208; C91-C95	2,584	1.06	0.98-1.14	0.99	0.93-1.06

<sup>a</sup> Age, race/ethnicity, gender stratified, and adjusted for baseline values of education, marital status, body mass index, body mass index squared, smoking status, cigarettes per day, cigarettes per day squared, duration of smoking, duration of smoking squared, age started smoking, passive smoking, vegetable/fruit/fiber consumption, fat consumption, beer, wine, liquor consumption, industrial exposures, occupation dirtiness index, and 1990 ecological covariates.

<sup>b</sup> As above but not gender stratified. Analysis limited to 344,593 women for analysis of breast cancer mortality, 235,637 women for analysis of uterine or cervical cancer mortality, and 228,494 women for analysis of ovarian cancer mortality. Analysis limited to 278,455 men for analysis of prostate cancer mortality.

<sup>c</sup> Women reporting a previous hysterectomy or an artificial menopause excluded here (n = 108,956).

<sup>d</sup> Women reporting having undergone an ovarian surgery also excluded here (n = 7,143).

Table S9. Adjusted HRs (95% CIs)<sup>a</sup> for non-lung cancer mortality per each fifth percentile–mean increment in air pollutant concentrations, stratified results according to selected risk factors, CPS-II cohort, US (1982-2004).

Stratification variable	PM <sub>2.5</sub>						NO <sub>2</sub>		
	Bladder			Kidney			Colorectal		
	Deaths n	HR	95% CI	Deaths n	HR	95% CI	Deaths n	HR	95% CI
		per 4.4 µg/m <sup>3</sup>			per 4.4 µg/m <sup>3</sup>			per 6.5 µg/m <sup>3</sup>	
Gender									
Men	986	<b>1.16</b>	<b>1.05-1.29</b>	586	<b>1.23</b>	<b>1.08-1.40</b>	3,375	<b>1.06</b>	<b>1.01-1.13</b>
Women	338	1.03	0.86-1.23	341	1.00	0.83-1.20	3,100	1.06	1.00-1.12
<i>p</i> value for interaction		0.25			0.13			0.79	
Smoking Status									
Never cigarettes, pipes, or cigars	342	<b>1.21</b>	<b>1.01-1.44</b>	321	1.11	0.91-1.34	2,656	1.05	0.98-1.12
Current cigarette smoker only	358	1.07	0.89-1.27	217	<b>1.28</b>	<b>1.03-1.59</b>	1,249	1.06	0.97-1.16
Former cigarette smoker only	406	1.09	0.93-1.27	263	1.06	0.87-1.29	1,770	1.03	0.96-1.11
<i>p</i> value for interaction		0.50			0.30			0.80	
Educational Attainment									
<High School	260	1.07	0.86-1.33	148	1.20	0.89-1.60	1,040	<b>1.12</b>	<b>1.01-1.24</b>
High School	357	1.04	0.87-1.24	290	1.13	0.92-1.39	2,156	<b>1.15</b>	<b>1.07-1.23</b>
>High School	707	<b>1.18</b>	<b>1.05-1.33</b>	489	1.14	0.99-1.32	3,279	0.99	0.94-1.05
<i>p</i> value for interaction		0.67			0.97			<b>0.03</b>	

<sup>a</sup> Age, race/ethnicity, gender stratified, and adjusted for baseline values of education, marital status, body mass index, body mass index squared, smoking status, cigarettes per day, cigarettes per day squared, duration of smoking, duration of smoking squared, age started smoking, passive smoking, vegetable/fruit/fiber consumption, fat consumption, beer, wine, liquor consumption, industrial exposures, occupation dirtiness index, and 1990 ecological covariates where appropriate.